Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Psyence Group (CSE:PSYG) has received approval for its Phase IIa clinical trial from the Medicines and Healthcare products Regulatory Agency
  • The clinical trial will assess the efficacy and safety of psilocybin-assisted psychotherapy versus psychotherapy alone for the treatment of adjustment disorder due to an incurable cancer diagnosis
  • Psyence has partnered with a psychedelic contract research organization, Clerkenwell Health, to design and deliver the clinical trial at two centres in the United Kingdom
  • Psyence CEO, Dr. Neil Maresky, sat down with Daniella Atkinson to discuss the news
  • Psysence Group Inc. (PSYG) opened trading at C$0.10 per share

Psyence Group (CSE:PSYG) has received approval for its Phase IIa clinical trial from the Medicines and Healthcare products Regulatory Agency (MHRA).

This is the UK’s equivalent regulatory body to Canada’s Health Canada and the US’s FDA. The clinical trial will assess the efficacy and safety of psilocybin-assisted psychotherapy versus psychotherapy alone for the treatment of adjustment disorder due to an incurable cancer diagnosis.

Psyence has partnered with a psychedelic contract research organization, Clerkenwell Health, to design and deliver the clinical trial at two centres in the United Kingdom.

Psyence CEO Dr. Neil Maresky sat down with Daniella Atkinson to discuss the news.

“It is a privilege to conduct research with psilocybin that may result in significant improvements in patients’ lives. We are thrilled that we can now progress this important trial.”

Psyence is a public life science biotechnology company with a focus on natural psychedelics. Psyence works with natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care.

Pysence operates one of the world’s first federally licensed commercial psilocybin mushroom cultivation and production facilities in Lesotho, Southern Africa.

Psysence Group Inc. (PSYG) opened trading at C$0.10 per share.


More From The Market Herald

" Successful gold explorer makes NEW polymetallic discovery

Northstar Gold has been making headlines over the past couple of years advancing its high-grade flagship Miller Gold Property.

" From corporate launch to upcoming initial resource estimate, here’s one of 2022’s top lithium performers

Lithium Ionic Corp. has been hailed as the multi-billion-dollar blueprint next door by analysts.

" @ the Bell: Growth-sensitive stocks fluctuate on mega jobs report

Canada’s main stock index ended on the higher side of flat on Friday trading as strength in the energy and technology sectors was weighed against
The Market Herald Video

" Trillion Energy (CSE:TCF) to commence 3D seismic reprocessing project for SASB

Trillion Energy (TCF) has announced the commencement of its 3D seismic reprocessing project for SASB.